Single-centre survival analysis over 10 years after MR-guided radiofrequency ablation of liver metastases from different tumour entities.
Long time overall survival
MR-based radiofrequency ablation
Minimal invasive tumour ablation
Journal
Insights into imaging
ISSN: 1869-4101
Titre abrégé: Insights Imaging
Pays: Germany
ID NLM: 101532453
Informations de publication
Date de publication:
21 Mar 2022
21 Mar 2022
Historique:
received:
29
09
2021
accepted:
09
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Radiofrequency ablation (RFA) is a minimal-invasive, local therapy in patients with circumscribed metastatic disease. Although widely used, long time survival analysis of treated liver metastases is still pending while also analysing the patients' experience of MR-based radiofrequency. Monocentric, retrospective analysis of long-time overall and progression free survival (OS; PFS) of 109 patients, treated with MRI-guided hepatic RFA between 1997 and 2010, focusing on colorectal cancer patients (CRC). Complimentary therapies were evaluated and Kaplan Meier-curves were calculated. Patients' experience of RFA was retrospectively assessed in 28 patients. 1-, 3-, 5-, 10-year OS rates of 109 patients with different tumour entities were 83.4%, 53.4%, 31.0% and 22.9%, median 39.2 months, with decreasing survival rates for larger metastases size. For 72 CRC patients 1-, 3-, 5-, 10-year OS rates of 90.2%, 57.1%, 36.1% and 26.5% were documented (median 39.5 months). Thereof, beneficial outcome was detected for patients with prior surgery of the CRC including chemotherapy (median 53.0 months), and for liver metastases up to 19 mm (28.5% after 145 months). Hepatic PFS was significantly higher in patients with liver lesions up to 29 mm compared to larger ones (p = 0.035). 15/28 patients remembered RFA less incriminatory than other applied therapies. This is the first single-centre, long-time OS and PFS analysis of MRI-guided hepatic RFA of liver metastases from different tumour entities, serving as basis for further comparison studies. Patients' experience of MR based RFA should be analysed simultaneously to the performed RFA in the future.
Sections du résumé
BACKGROUND
BACKGROUND
Radiofrequency ablation (RFA) is a minimal-invasive, local therapy in patients with circumscribed metastatic disease. Although widely used, long time survival analysis of treated liver metastases is still pending while also analysing the patients' experience of MR-based radiofrequency.
METHODS
METHODS
Monocentric, retrospective analysis of long-time overall and progression free survival (OS; PFS) of 109 patients, treated with MRI-guided hepatic RFA between 1997 and 2010, focusing on colorectal cancer patients (CRC). Complimentary therapies were evaluated and Kaplan Meier-curves were calculated. Patients' experience of RFA was retrospectively assessed in 28 patients.
RESULTS
RESULTS
1-, 3-, 5-, 10-year OS rates of 109 patients with different tumour entities were 83.4%, 53.4%, 31.0% and 22.9%, median 39.2 months, with decreasing survival rates for larger metastases size. For 72 CRC patients 1-, 3-, 5-, 10-year OS rates of 90.2%, 57.1%, 36.1% and 26.5% were documented (median 39.5 months). Thereof, beneficial outcome was detected for patients with prior surgery of the CRC including chemotherapy (median 53.0 months), and for liver metastases up to 19 mm (28.5% after 145 months). Hepatic PFS was significantly higher in patients with liver lesions up to 29 mm compared to larger ones (p = 0.035). 15/28 patients remembered RFA less incriminatory than other applied therapies.
CONCLUSIONS
CONCLUSIONS
This is the first single-centre, long-time OS and PFS analysis of MRI-guided hepatic RFA of liver metastases from different tumour entities, serving as basis for further comparison studies. Patients' experience of MR based RFA should be analysed simultaneously to the performed RFA in the future.
Identifiants
pubmed: 35312842
doi: 10.1186/s13244-022-01178-8
pii: 10.1186/s13244-022-01178-8
pmc: PMC8938560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
48Informations de copyright
© 2022. The Author(s).
Références
World J Surg Oncol. 2018 Oct 15;16(1):207
pubmed: 30322402
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):283-90
pubmed: 25589357
Cancer Imaging. 2020 May 27;20(1):37
pubmed: 32460898
Eur J Gastroenterol Hepatol. 2013 Apr;25(4):442-6
pubmed: 23470267
AJR Am J Roentgenol. 2018 Apr;210(4):883-890
pubmed: 29446675
Invest Radiol. 2013 Jun;48(6):429-36
pubmed: 23511192
Eur J Surg Oncol. 2007 Aug;33(6):752-6
pubmed: 17408907
Br J Surg. 2013 Oct;100(11):1505-14
pubmed: 24037573
Liver Transpl Surg. 1999 Jan;5(1):65-80
pubmed: 9873095
J Magn Reson Imaging. 2007 Oct;26(4):1043-52
pubmed: 17896364
Eur J Cancer. 2009 Jul;45(10):1748-56
pubmed: 19356924
Oncologist. 2019 Oct;24(10):e990-e1005
pubmed: 31217342
Eur Radiol. 2009 May;19(5):1206-13
pubmed: 19137310
Eur J Radiol. 2014 Jan;83(1):111-6
pubmed: 24161781
J Magn Reson Imaging. 2009 Jun;29(6):1308-16
pubmed: 19418557
Eur Radiol. 2012 Sep;22(9):1972-82
pubmed: 22527377
Visc Med. 2017 Mar;33(1):62-68
pubmed: 28612019
J Magn Reson Imaging. 1998 Jan-Feb;8(1):40-7
pubmed: 9500259
Ann Surg. 2010 May;251(5):796-803
pubmed: 19858704
Tech Vasc Interv Radiol. 2013 Dec;16(4):219-29
pubmed: 24238377
Cancer Res Treat. 2004 Apr;36(2):128-31
pubmed: 20396552
Eur J Radiol. 2017 Sep;94:85-92
pubmed: 28655432
J Magn Reson Imaging. 2004 Mar;19(3):342-8
pubmed: 14994303
Surg Oncol. 2007 Jul;16(1):47-51
pubmed: 17499499
Acta Oncol. 2010;49(2):192-200
pubmed: 20059314